Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | FABP6 | P51161 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.33 |
| ▸ | FEN1 | P39748 | 3/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6264453 | 0.89 | UHRF1 (0.41) | GAAALDH1A1HSD17B10MAPTADRA2A | |
| SCHEMBL4716840 | 0.78 | MAPT (0.40) | GAAALDH1A1HSD17B10MAPTADRA2A | |
| SCHEMBL6107503 | 0.78 | ALDH1A1 (0.40) | GAAALDH1A1HSD17B10MAPTADRA2A | |
| SCHEMBL29659230 | 0.78 | MAPT (0.40) | GAAALDH1A1HSD17B10MAPTADRA2A | |
| SCHEMBL4716839 | 0.78 | ALDH1A1 (0.40) | GAAALDH1A1HSD17B10MAPTADRA2A | |
| SCHEMBL23860863 | 0.78 | ALDH1A1 (0.40) | GAAALDH1A1HSD17B10MAPTADRA2A | |
| SCHEMBL13212813 | 0.78 | ALDH1A1 (0.40) | GAAALDH1A1HSD17B10MAPTADRA2A | |
| SCHEMBL29364018 | 0.78 | ALDH1A1 (0.40) | GAAALDH1A1HSD17B10MAPTADRA2A | |
| SCHEMBL2596436 | 0.78 | MAPT (0.40) | GAAALDH1A1HSD17B10MAPTADRA2A | |
| SCHEMBL21400681 | 0.77 | ALDH1A1 (0.44) | GAAALDH1A1HSD17B10MAPTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | MERCK SHARP & DOHME CORP. (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023109521-A1 | PARP INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 凯复(苏州)生物医药有限公司 | 2023-06-22 | — | — | WO | disclosed |
| EP-3538525-B1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022089219-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-05-05 | — | — | WO | disclosed |
| WO-2021259208-A1 | TYK-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-12-30 | — | — | WO | disclosed |
| EP-3929185-A1 | NITROGEN-CONTAINING FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2021-12-29 | — | — | EP | disclosed |
| US-20210346364-A1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-11-11 | — | — | US | disclosed |
| EP-3538527-B1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-09-22 | — | — | US | disclosed |
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| US-6900232-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-6855722-B2 | Substituted indoles and their use as integrin antagonists | DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040259869-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2004-12-23 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | disclosed |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322803-A1 | SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | DDX21, HRAS, RPL17 | GAA 3171/4885ALDH1A1 1946/4885HSD17B10 1771/4885 |
| US-20210346364-A1 | OXAZOLIDINONES AS TARO INHIBITORS | OXA1L, DDO, ALPI | GAA 129/4885ALDH1A1 2627/4885HSD17B10 384/4885 |
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | ADGRE5, ITGA5, ADGRF1 | GAA 3017/4885ALDH1A1 948/4885HSD17B10 1884/4885 |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | GAA 4743/4885ALDH1A1 1690/4885HSD17B10 3516/4885 |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | GAA 2476/4885ALDH1A1 666/4885HSD17B10 2341/4885 |
| US-20040259869-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | ITGA5, ITGB5, ITGB3 | GAA 2288/4885ALDH1A1 552/4885HSD17B10 2202/4885 |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGAL, ITGA5 | GAA 4739/4885ALDH1A1 1662/4885HSD17B10 3766/4885 |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | ITGA5, ITGB5, ITGB3 | GAA 2288/4885ALDH1A1 552/4885HSD17B10 2202/4885 |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | OXA1L, DDO, ALPI | GAA 129/4885ALDH1A1 2627/4885HSD17B10 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.